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Abstract
Recent studies have shown a significant increase in the temporal trend of medullary 
thyroid carcinoma (MTC) incidence. However, it remains unknown to which extent 
sporadic medullary thyroid carcinoma (SMTC) and hereditary MTC (HMTC) affect the MTC 
incidence over time. We conducted a nationwide retrospective study using previously 
described RET and MTC cohorts combined with review of medical records, pedigree 
comparison and relevant nationwide registries. The study included 474 MTC patients 
diagnosed in Denmark between 1960 and 2014. In the nationwide period from 1997 to 
2014, we recorded a mean age-standardized incidence of all MTC, SMTC and HMTC of 
0.19, 0.13 and 0.06 per 100,000 per year, respectively. The average annual percentage 
change in incidence for all MTC, SMTC and HMTC were 1.0 (P = 0.542), 2.8 (P = 0.125) and 
−3.1 (P = 0.324), respectively. The corresponding figures for point prevalence at January 
1, 2015 were 3.8, 2.5 and 1.3 per 100,000, respectively. The average annual percentage 
change in prevalence from 1998 to 2015 for all MTC, SMTC and HMTC was 2.8 (P < 0.001), 
3.8 (P < 0.001) and 1.5 (P = 0.010), respectively. We found no significant change in the 
incidence of all MTC, SMTC and HMTC possibly due to our small sample size. However, 
due to an increasing trend in the incidence of all MTC and opposing trends of SMTC 
(increasing) and HMTC (decreasing) incidence, it seems plausible that an increase for all 
MTC seen by others may be driven by the SMTC group rather than the HMTC group.
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Introduction
Medullary thyroid carcinoma (MTC) is a neuroendocrine 
tumor arising from the calcitonin secreting parafollicular 
C cells of the thyroid gland. MTC is divided into sporadic 
MTC (SMTC) and hereditary MTC (HMTC) accounting 
for approximately 75% and 25%, respectively. HMTC 
occurs as part of the autosomal dominant inherited 
cancer syndromes, multiple endocrine neoplasia 
(MEN) 2A and MEN2B. MEN2A and MEN2B account 
for approximately 95% and 5% of all MEN2 patients, 
respectively. MEN2A associates MTC, pheochromocytoma 
(PHEO), hyperparathyroidism (HPTH), cutaneous lichen 
amyloidosis and Hirschsprung’s disease, while MEN2B 
associates MTC, PHEO, ganglioneuromatosis of the 
aerodigestive tract, and facial, ophthalmologic and skeletal 
abnormalities. Both syndromes are caused by germline 
mutations of the REarranged during Transfection (RET) 
proto-oncogene (1, 2).
Recent studies have shown a significant increase in 
the temporal trend of MTC incidence (3, 4, 5, 6, 7, 8). 
However, it remains unknown to which extent SMTC and 
HMTC affect the MTC incidence over time.
Consequently, we conducted the first nationwide 
study aiming to assess the significance of SMTC and 
HMTC in regards to the time trends in MTC incidence. 
Additionally, we describe prevalence changes over time.
Patients and methods
Patients
This retrospective cohort study included 474 unique 
patients diagnosed with MTC in Denmark between 
January 1, 1960 and December 31, 2014. Of these, 356 
were classified as SMTC and 113 as HMTC. Five were left 
unclassified.
An MTC cohort, initially comprising 476 patients 
diagnosed with MTC in Denmark between January 
1960 and December 2014, was constructed through 
three nationwide registries: the Danish Thyroid Cancer 
(DATHYRCA) Database, the Danish Cancer Registry and 
the Danish Pathology Register (9, 10, 11). This has been 
described in detail elsewhere (12). We only included 
patients with a histological or cytological MTC diagnosis, 
which was the case for 474 and 2 patients, respectively. 
Two of the 476 MTC patients were excluded as they were 
diagnosed in Denmark, while being inhabitants of the 
Faroe Islands. This resulted in 474 MTC patients eligible 
for the study.
In order to molecularly classify the MTC patients 
as having either SMTC or HMTC, the MTC cohort was 
cross-checked with the nationwide Danish RET cohort 
containing all patients (n = 1583) RET tested in Denmark 
from September 1994 to December 2014. The RET cohort 
has been described in detail previously (13). Patients 
were classified as HMTC if tested positive for a RET 
sequence change classified as pathogenic in the ARUP 
MEN2 database on April 1, 2018 (14). If tested negative, 
patients were classified as SMTC. Cross-check between the 
MTC and RET cohort revealed that 272 of the 474 MTC 
patients had been RET tested, while 202 patients had 
not been tested. Five of the 272 patients were tested by 
a method for detecting the C611Y mutation only (15). 
Consequently, 207 MTC patients were not adequately 
molecularly classified. Among the 267 MTC patients 
eligible for molecular classification, 91 and 176 were 
classified as HMTC and SMTC, respectively (Fig. 1).
To classify the 207 molecularly unclassified MTC 
patients, several sources were used.
First, a review of available medical records (n = 149) 
was undertaken. This revealed that one patient had been 
tested positive for the C634R mutation subsequent to 
the end date of the RET cohort December 31, 2014, and 
thus reduced the number of molecularly unclassified 
patients to 206. The remaining patients were classified 
as HMTC, if there was presence of: 1) a family history 
of MEN2 (MTC, PHEO, HPTH, Hirschsprung’s disease, 
cutaneous lichen amyloidosis, mucosal neuromas/
ganglioneuromatosis) or 2) a MEN2 feature (histologically 
verified PHEO, Hirschsprung’s disease, clinically diagnosed 
cutaneous lichen amyloidosis or mucosal neuromas/
ganglioneuromatosis, or histologically and biochemically 
diagnosed HPTH) other than their MTC. Patients were 
classified as apparently SMTC, if there was no presence of 
MEN2 family history and no MEN2 features other than 
their MTC.
Secondly, relatedness to a nationwide cohort of 
RET positive MEN2 families was assessed through 
pedigree comparison. This was performed to improve 
classification, as RET germline mutations have been 
reported in 1.5–14.9% of patients, who have been 
classified as apparently SMTC in absence of MEN2 
family history or other MEN2 features (16, 17, 18, 19, 
20, 21, 22). Feasibility of this exercise was based on data 
indicating that de novo mutations occur in only 5.6–9% 
of MEN2A patients (23), leading to the assumption of a 
high likelihood of relatedness to our nationwide cohort 
of RET-positive MEN2A families, if a patient had HMTC. 
From the nationwide Danish RET cohort, 36 RET positive 
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families were identified (13). Five families (one MEN2A 
and four MEN2B (three of which have been described 
elsewhere (24, 25, 26, 27)) were excluded, as mutations 
of the index patient had been molecularly proven as 
de novo. One family was excluded, as the pathogenicity 
of the RET I852M variant recently has been questioned 
and re-classified in the ARUP MEN2 database (14, 28). 
Three families (C634Y, C634Y/Y791F and L790F) were 
excluded, due to origin outside Denmark. Meanwhile, we 
included the family of the aforementioned C634R patient. 
This yielded 28 RET-positive families (Table  1). Several 
of these have been studied earlier (29, 30, 31, 32, 33). 
A pedigree for each RET-positive family was created 
with a minimum of four generations by use of the 
Civil Registration System (www.cpr.dk) and the Danish 
National Archives (www.sa.dk/en/). Similarly, a pedigree 
for each of the 206 molecularly unclassified MTC patients 
was created. Four-generation pedigrees were created for 
154 patients. Three-, two- and one-generation pedigrees 
were created for 16, 18 and 18 patients, respectively. 
Figure 1
Flow chart showing 474 patients with medullary 
thyroid carcinoma classified into the sporadic or 
hereditary type. Dotted boxes indicate methods 
used. MTC, medullary thyroid carcinoma; SMTC, 
sporadic MTC; HMTC, hereditary MTC; RET, 
rearranged during transfection; MEN, multiple 
endocrine neoplasia. aOne patient RET tested 
subsequent to the end date of the RET cohort in 
December 31, 2014.
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Once an individual was born abroad or as an illegitimate 
child, their ancestors often could not be traced. This was 
the case in all but three pedigrees where four generations 
could not be reached. All pedigrees with >1 generation 
(n = 188) were compared to the pedigrees of the 28 RET-
positive families. If relatedness between an MTC patient 
and a RET-positive family could be proven, the MTC 
patient was considered to carry the family RET mutation, 
and thus classified as HMTC. If no relatedness, patients 
were classified as SMTC.
When using both medical records and pedigree 
comparison to classify the 206 molecularly unclassified 
patients, 21 and 180 fulfilled the criteria for HMTC and 
SMTC, respectively (Table  2). Five patients could not 
be classified, as medical records were unavailable and 
pedigrees with >1 generation could not be created (Fig. 1).
Thirdly, the cohort of molecularly unclassified 
MTC patients was cross-checked with relevant cohorts 
identified through two nationwide registries: Danish 
Pathology Register and the Danish National Patient 
Registry (11, 34). Details can be seen in Supplementary 
Material (see section on supplementary data given at 
the end of this article). This was carried out to identify 
MEN2 features in MTC patients without medical records 
and to ensure that MEN2 features besides MTC had not 
been overlooked in the patients with available medical 
records. With this exercise, we depleted all register-based 
possibilities for classification, but revealed no HMTC 
patients, not classified already by medical records and 
pedigree comparison (Fig. 1).
Therefore, we ended up with 356 SMTC, 113 HMTC 
and five unclassified. Table  2 shows the methods and 
criteria used for classification according to time periods.
The investigation was approved by the Danish Health 
Authority (3-3013-395/3) and the Danish Data Protection 
Agency (18/17801).
Methods
The MTC cohort was based on the Danish Cancer Registry, 
the Danish Pathology Register and the Danish Thyroid 
Cancer Database, which have prospectively collected data 
Table 1 Families with detected RET germline mutationsa and Danish origin included in this study.
Family no. Exon Nucleotide change Sequence change RET+b/RET− Reference
1 10 c.1833C>G C611W 6/11
2 10 c.1832G>A C611Y 2/0 (29)
3 10 c.1832G>A C611Y 1/0
4 10 c.1832G>A C611Y 8/3
5 10 c.1832G>A C611Y 15/13
6 10 c.1832G>A C611Y 2/0 (32)
7 10 c.1832G>A C611Y 9/7 (32)
8 10 c.1832G>A C611Y 2/6
9 10 c.1832G>A C611Y 26/27
10 10 c.1832G>A C611Y 30/30 (30)
11 10 c.1832G>A C611Y 1/3
12 10 c.1832G>A C611Y 5/18 (31)
13 10 c.1832G>A C611Y 7/8
14 10 c.1853G>T C618F 1/1
15 10 c.1853G>T C618F 2/1 (32)
16 10 c.1853G>A C618Y 5/9
17 10 c.1853G>A C618Y 3/3 (32)
18 10 c.1858T>C C620R 6/5 (33)
19 10 c.1858T>C C620R 3/3 (32)
21 11 c.1891G>T D631Y 1/0
22 11 c.1900T>C C634R 2/0
23 11 c.1900T>C C634R 1/2 (32)
24 11 c.1900T>C C634R 3/11 (30)
25 11 c.1900T>C C634R 1/5 (32)
29 14 c.2410G>A V804M 2/1
34 16 c.2753T>C M918T 1/2
36 16 c.2753T>C M918T 1/1
37 11 c.1900T>C C634R 1/0
Modified from Table 2 of Mathiesen et al. (13).
aSequence changes classified as pathogenic in the ARUP MEN2 database April 1, 2018 (14); bRET+ includes index cases.
RET, rearranged during transfection.
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since 1943, 1968 and 1996, respectively. The first year, in 
which registration was mandatory in all three registries 
simultaneously, was 1997. This led us to subdivide the 
inclusion period into an uncertain period (1960–1996) 
where complete coverage could not be guaranteed, and 
a nationwide period (1997–2014) where coverage of the 
entire country was considered complete. In this paper, we 
primarily focus on the latter period.
Incidence
Incidence was calculated as the number of all MTC, 
SMTC and HMTC patients diagnosed per year divided 
by the number of inhabitants alive in the corresponding 
year. To ease comparison, incidence standardization was 
performed according to the World (WHO 2000–2025), the 
2000 USA, the European (Scandinavian 1960), the World 
(Segi 1960) and the 1970 Swedish population. Population 
data and weights were retrieved from the National Cancer 
Institute (www.seer.cancer.gov/stdpopulations/) and 
Statistics Sweden (www.scb.se/en/).
The population at risk (inhabitants alive in Denmark) 
was roughly constant throughout the years used for 
incidence calculations. Danish population data were 
supplied by Statistics Denmark (www.statbank.dk).
Prevalence
Point prevalence for each year from 1961 to 2015 was 
calculated as the number of all MTC, HMTC and SMTC 
patients alive at January 1st divided by the number of 
inhabitants alive at the same date.
Statistical analysis
Age at diagnosis was normally distributed in all groups 
and reported as mean with 95% CI. Direct standardization 
was used to age-standardize incidences to standard 
populations. Poisson regression models were applied 
to estimate time trends in incidence and prevalence by 
annual percentage change, while the Student’s t-test was 
used for comparison of means. P values below 0.05 were 
Table 2 Methods and criteria used for classification of 474 patients with medullary thyroid carcinoma in Denmark 1960–2014.
Category Methods Criteria 1960–1996 (n (%)) 1997–2014 (n (%)) 1960–2014 (n (%))
SMTC RET testing No RET mutationa detected 47 (19) 129 (58) 176 (37)
Pedigree comparison 
and medical record 
review
No relatedness to RET positive 
familyb and no MEN2 featurec other 
than MTC and no presence of MEN2 
family historyd
79 (32) 37 (17) 116 (24)
Pedigree comparison 
only
No relatedness to RET positive family 49 (20) 2 (1) 51 (11)
Medical record 
review only
No MEN2 feature other than MTC 
and no presence of MEN2 family 
history
10 (4) 3 (1) 13 (3)
Total 185 (74) 171 (76) 356 (75)
HMTC RET testing RET mutation detected 39 (16) 53 (24) 92 (19)
Pedigree comparison 
and medical record 
review
Relatedness to RET positive family 
and/or MEN2 feature other than 
MTC and/or presence of MEN2 
family history
15e (6) 0 (0) 15e (3)
Pedigree comparison 
only
Relatedness to RET positive family 2e (1) 0 (0) 2e (0)
Medical record 
review only
MEN2 feature other than MTC and 
no presence of MEN2 family history
4f (2) 0 (0) 4f (1)
Total 60 (24) 53 (24) 113 (24)
Unclassified 5 (0) 0 (0) 5 (1)
All 250 (100) 224 (100) 474 (100)
Due to rounding up, not all sums of percentages fit.
aSequence changes classified as pathogenic in the ARUP MEN2 database April 1, 2018 (14); bRET positive family defined as a family from Table 1; cMEN2 
feature defined as histologically verified pheochromocytoma, Hirschsprung’s disease, clinically diagnosed cutaneous lichen amyloidosis or mucosal 
neuromas/ganglioneuromatosis, or histologically and biochemically diagnosed hyperparathyroidism; dMEN2 family history defined as history of MTC, 
pheochromocytoma, hyperparathyroidism, Hirschsprung’s disease, cutaneous lichen amyloidosis or mucosal neuromas/ganglioneuromatosis; eDue to 
relatedness to RET positive families, all 17 patients were considered RET mutation carriers: one C611W, twelve C611Y, one 618Y, one D631Y, one 634R 
and one V804M; fAll patients had phenotypically MEN2B and have been described elsewhere (12).
HMTC, hereditary MTC; MEN2, multiple endocrine neoplasia 2; MTC, medullary thyroid carcinoma; RET, rearranged during transfection; SMTC, sporadic MTC.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-18-0157
http://www.endocrineconnections.org © 2018 The authors
Published by Bioscientifica Ltd
J S Mathiesen et al. Incidence and prevalence of 
SMTC and HMTC
8347:6
considered significant. All analyses were done using Stata 
14.2 (StataCorp, USA).
Results
Demographics and genetic characteristics are described 
in Table 3. In the nationwide period from 1997 to 2014, 
the female-to-male ratio for all MTC, SMTC and HMTC 
were 1.43 (95% CI: 1.05–1.82), 1.63 (95% CI: 1.13–2.13) 
and 0.96 (95% CI: 0.44–1.48), respectively. In the same 
period, the mean age at diagnosis for all MTC patients 
was 52.4 (95% CI: 49.9–54.8) years, while a significant 
difference was identified between the SMTC and HMTC 
group (P < 0.001).
Incidence
The mean and annual age-standardized (World (WHO 
2000–2025)) incidences of all MTC, SMTC and HMTC in 
the nationwide period are shown in Table 4.
The age-standardized (World (WHO 2000–2025)) 
incidence of all MTC increased from 0.21 per 100,000 
in 1997 to 0.28 per 100,000 in 2014, corresponding to 
an average annual percentage change of 1.0 (95% CI: 
−2.2 to 4.4; P = 0.542). In the same period, the average 
annual percentage change for SMTC and HMTC was 2.8 
(95% CI: −0.8 to 6.6; P = 0.125) and −3.1 (95% CI: −9.0 
to 3.2; P = 0.324), respectively (Supplementary Figure 1). 
Similar non-significant time trends were seen when age-
standardizing to the other standard populations.
Prevalence
The point prevalence at January 1, 2015, for all 
MTC, SMTC and HMTC was 3.8 (95% CI: 3.3–4.3), 
2.5 (95% CI: 2.1–2.9) and 1.3 (95% CI: 1.0–1.6) per 
100,000, respectively (215 MTC, 141 SMTC and 74 HMTC 
patients and 5,659,715 inhabitants).
The average annual percentage change from 
January 1, 1998, to January 1, 2015, for all MTC, 
SMTC and HMTC was 2.8 (95% CI: 2.1–3.6; P < 0.001), 
Table 3 Demographic and genetic characteristics of 474 patients with medullary thyroid carcinoma in Denmark, 1960–2014.
Category 1960–1996 1997–2014 1960–2014
SMTC
 Total 185 171 356
 Female:male 104:81 106:65 210:146
 Mean age at diagnosis, years (95% CI) 57.9 (55.5–60.3) 57.1 (54.7–59.4) 57.5 (55.8–59.2)
 Diagnosed by autopsy 13 4 17
HMTC
 Total 60 53 113
 Female:male 28:32 26:27 54:59
 Mean age at diagnosis, years (95% CI) 44.8 (40.3–49.4) 37.2 (32.4–42.0) 41.2 (37.9–44.6)
 Diagnosed by autopsy 1 0 1
 RET mutation carriers
  C611W 1 3 4
  C611Y 40 31 71
  C618F 1 1 2
  C618Y 2 3 5
  C620R 3 4 7
  D631Y 1 0 1
  C634R 7 1 8
  C634R + Y791F 0 1 1
  L790F 0 1 1
  V804M 1 1 2
  A883F 0 1 1
  M918T 0 6 6
  Unknown 4a 0 4a
Unclassified
 Total 5 0 5
 Female:male 3:2 3:2
 Mean age at diagnosis, years (95% CI) 59.0 (47.2–70.8) 59.0 (47.3–70.8)
 Diagnosed by autopsy 1 1
Figures indicate number of patients unless otherwise stated.
aAll patients had phenotypically MEN2B and have been described elsewhere (12).
HMTC, hereditary medullary thyroid carcinoma; RET, rearranged during transfection; SMTC, sporadic medullary thyroid carcinoma.
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3.8 (95% CI: 2.8–4.8; P < 0.001), 1.5 (95% CI: 0.4–2.6; 
P = 0.010), respectively (Fig. 2).
Discussion
In the nationwide period of this study, we report of a 
statistically non-significant increase in incidence for all 
MTC and SMTC, and similarly a non-significant decrease 
for HMTC. Prevalence increased significantly from 1998 
to 2015.
Limitations
To estimate the true number of SMTC and HMTC 
patients during a given time period, every MTC patient 
is preferably molecularly classified. This was the case 
for 182 of 224 (81%) patients in our nationwide period 
from 1997 to 2014 (Table 2). Of the remaining 42 (19%) 
patients, four were diagnosed at autopsy, while 21 were 
dead and 17 were alive at October 1, 2017. Ideally, RET 
testing would be offered to those alive and performed in 
normal tissue from the deceased (33). However, this is 
a burdensome affair associated with substantial ethical 
challenges. Instead, classification was based on relatedness 
to RET positive families by pedigree comparison along 
with MEN2 features other than MTC and the presence of 
MEN2 family history in the vast majority of molecularly 
unclassified patients (Table 2).
When comparing the two inclusion periods, 
1960–1996 and 1997–2014, the former is >twice as long 
as the latter, but include an almost identical number of 
patients. This could reflect an increasing incidence or poor 
registration in the early years. To comply with the latter 
and ensure complete coverage, we primarily focused on 
the years 1997–2014, even though registration to the two 
nationwide registries, the Danish Cancer Registry and the 
Danish Thyroid Cancer Database, has been mandatory 
since 1987 and 1996, respectively (9, 10).
Demographics
In the nationwide period, the female-to-male ratio for all 
MTC was 1.43. This is in accordance with the ratio found 
in other epidemiologic studies on the subject (8, 35, 36, 
37, 38). As for virtually all sporadic thyroid cancers, this 
sex disparity still remains unexplained (39). The mean 
age at diagnosis of 52.4  years for all MTC patients was 
also comparable to that of other population-based series 
(8, 37). If only considering patients diagnosed at autopsy, 
female-to-male ratio and age at diagnosis were identical to 
other series (40).
Incidence
The mean age-standardized incidence of all MTC from 
1997 to 2014 did not differ significantly from that reported 
by large-scale studies with roughly equivalent inclusion 
periods (4, 7). One could have expected a higher incidence 
of MTC in Denmark, due to the RET C611Y founder 
effect (41). This may in part be explained by the absence 
of MTC in 49% (29/59) of the Danish C611Y carriers 
thyroidectomized during the same period. Additionally, 
the distribution of RET germline mutations in Denmark and 
their corresponding MTC risk level need to be taken into 
account. Thus, compared to other populations, Denmark 
has a sparse representation of codon 634 mutation 
carriers, whose mutations are categorized in the ‘high’ 
risk level, while having a high representation of C611Y 
carriers, whose mutation is categorized in the ‘moderate’ 
risk level (1, 13). Accordingly, the MTC of a C611Y carrier 
is more likely to pass unrecognized compared to that of a 
codon 634 mutation carrier, potentially influencing the 
MTC incidence. Also, it is possible that MTC diagnosis 
is more easily avoided by prophylactic thyroidectomy in 
C611Y carriers as MTC is believed to develop later than in 
codon 634 mutation carriers.
In the present study, we found no significant change 
in incidence of all MTC between 1997 and 2014. Similarly, 
studies including populations from Brazil, the USA, 
the Netherlands, Italy and France also failed to detect a 
significant change during roughly comparable periods 
(38, 42, 43, 44, 45). However, two recent USA studies 
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Figure 2
Point prevalence of medullary thyroid carcinoma per 100,000 in Denmark 
at January 1, 1961–2015. MTC, medullary thyroid carcinoma; SMTC, 
sporadic MTC; HMTC, hereditary MTC..
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based on Surveillance, Epidemiology, and End Results 
13 data, reported a significant increase in all MTC from 
1992/1993 to 2012 (5, 7). One of the studies reported a 
1.87% average annual change in incidence from 1993 
to 2012, but did not elaborate on the number of MTC 
patients (5). The other study included 1579 MTC patients 
and computed a 2.3% average annual incidence change 
from 1992 to 2012 (7). After age standardization to the 
2000 USA population for suitable comparison, the average 
annual percentage change for all MTC in Denmark in 
the corresponding period was 0.7 (95% CI: −1.7 to 3.2; 
P = 0.559). The absence of significant change in Denmark 
may well be a question of sample size.
For the first time since RET testing has become 
available, we have calculated the mean annual incidence 
for SMTC and HMTC. This has been done only once before 
RET testing became available. Thus, a Swedish nationwide 
study, covering the period from 1970 to 1981, reported 
the mean age-standardized incidence of SMTC and HMTC 
as 0.15 and 0.06 per 100,000 per year, respectively (40). 
During the same period, the mean age-standardized (1970 
Sweden) incidences in Denmark for SMTC and HMTC were 
0.12 (95% CI: 0.09–0.15) and 0.03 (95% CI: 0.02–0.05) per 
100,000 per year, respectively. One might have expected 
a higher incidence in Denmark compared to Sweden due 
to RET C611Y founder effect in Denmark (41). However, 
potential differences in the Danish and Swedish coverage 
in this period hinder reasonable conclusions.
The present study computed time trends for the 
incidence of SMTC and HMTC for the first time and showed 
an average annual change of 2.8% for SMTC and −3.1% for 
HMTC in the nationwide period. Systematically performed 
prophylactic thyroidectomy in two large C611Y families 
during the late 1970s and 1980s, one of which has been 
described earlier (30), may have precipitated or excluded 
several future MTC diagnoses, thus potentially contributing 
to the decreasing trend for HMTC incidence. A decreasing 
trend for MEN2 incidence could have a similar effect. This, 
however, seems less conceivable as the incidence of RET 
mutation carriers over time has been reported as either 
stable or increasing (46). Focusing only on prophylactic 
thyroidectomies performed from 1997 to 2014, little points 
toward a decreasing effect on temporal trends in HMTC 
incidence. In fact, based on the Danish RET cohort, the 
frequency of MTC in prophylactic thyroidectomized MEN2 
patients did not change significantly from 47% (22/47) 
during 1997–2005 to 63% (20/32) during 2006–2014. 
However, to accurately assess the effect of prophylactic 
thyroidectomy on HMTC incidence, our period of complete 
nationwide data is too short.
Although non-significant, the opposing temporal 
trends in SMTC and HMTC incidence could indicate 
that the temporal change of 1.0% in all MTC is driven 
by the SMTC group rather than the HMTC group. While 
remaining speculative, this may also apply for the large-
sample studies finding a significant increase in MTC 
incidence over time (3, 5, 6, 7, 8). This is supported by 
the significant increase in incidence reported for all major 
histological subtypes of non-hereditary thyroid cancer 
besides the anaplastic (5, 6).
Prevalence
At January 1, 2015, the point prevalence for all MTC 
was 3.8 per 100,000. To the best of our knowledge, the 
prevalence of MTC was unknown before this publication 
(18). However, the Orphanet has reported an estimated 
prevalence of 1–9 per 100,000 (www.orpha.net). Our 
prevalence lies within this estimate, but in the lower end.
We found a significant increase in prevalence for all 
MTC from 1998 to 2015. As the incidence did not change 
significantly in this period, a likely explanation could 
be an improvement in survival. After dichotomizing the 
nationwide period into two equal halves, no difference 
was seen in overall survival (P = 0.573, log-rank test). Thus, 
the prevalence increase does not seem to be explained by 
a recent improvement in survival. However, comparison 
of patients diagnosed in the two periods, 1960–1996 and 
1997–2014, demonstrated an improved overall survival 
over time (P < 0.001, log-rank test) that may potentially 
explain the increasing prevalence. Admittedly, one has to 
keep in mind the limitations of this comparison due to 
the potential disparity in period coverage. However, an 
improved survival in MTC patients during the last four 
decades has been seen in other studies as well (8).
As 57% of MTC patients are not biochemically cured 
upon initial surgery and additional 5% develop biochemical 
recurrence later (47), the majority of MTC patients will 
require life-long follow-up due to hypercalcitonemia. The 
increasing prevalence, therefore, implicitly suggests that 
the number of MTC patients needing life-long follow-up 
is growing significantly, warranting increased attention to 
the management of this patient group.
Conclusion
We found no significant change in the incidence of all 
MTC, SMTC and HMTC possibly due to our small sample 
size. However, due to an increasing trend in the incidence 
of all MTC and opposing trends of SMTC (increasing) and 
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HMTC (decreasing) incidence, it seems plausible that an 
increase for all MTC seen by others may be driven by the 
SMTC group rather than the HMTC group.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
EC-18-0157.
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